{"schema_version":"secwatch.filing_event.v1","accession":"0001601830-25-000142","form_type":"8-K/A","ticker":"RXRX","cik":"0001601830","company_name":"RECURSION PHARMACEUTICALS, INC.","filed_at":"2025-08-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.465137+00:00","generated_at":"2026-05-17T09:13:22.326256+00:00","sec_items":["3.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Recursion issues 2.4M contingent shares to Rallybio after GLP tox milestone","bullets":["Milestone triggered by initiation of GLP toxicology study on August 25, 2025.","Issued 2,397,023 contingent shares at $5.2148/share, representing $12.5M value.","Shares issued to Rallybio as seller under July 2025 ENPP1 JV acquisition.","Prospectus supplement filed August 29, 2025 to register shares for resale.","Filing amends prior 8-K from July 8, 2025 regarding the original acquisition."],"urls":{"canonical":"https://secwatch.observer/filing/0001601830-25-000142","json":"https://secwatch.observer/filing/0001601830-25-000142.json","markdown":"https://secwatch.observer/filing/0001601830-25-000142.md","text":"https://secwatch.observer/filing/0001601830-25-000142.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1601830/000160183025000142/0001601830-25-000142-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1601830/000160183025000142/rxrx-20250708.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T09:13:22.326256+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}